厄达替尼治疗尿路上皮癌的效果

The U.S. FDA has approved it for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have FGFR3 or FGFR2 gene mutations and whose disease has progressed during or after platinum-based chemotherapy, including patients within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy. This is the first FDA-approved targeted therapy for metastatic bladder cancer.

The effect of erdafitinib in the treatment of urothelial cancer:

A clinical trial was evaluable for efficacy in 87 patients who had progressed before or after at least one line of chemotherapy and had at least one of the following genetic alterations: FGFR3 gene mutations (R248C, S249C, G370C, Y373C) or FGFR gene fusions (FGFR3-tacc3, FGFR3-baiap2l1, FGFR2-BICC1, FGFR2-CASP7).

The main indicators evaluated in this clinical trial are objective response rate (the proportion of tumor shrinkage by more than 30%) and duration of response. The treatment results were: the objective response rate (ORR) was 32.2%, of which complete response (CR) was 2.3% and partial response (PR) was 29.9%; the median duration of response (DoR) was 5.4 months.

The therapeutic effects of patients with different gene mutations are: for FGFR3 mutations (n=64), the ORR is 40.6%; for FGFR3 fusions (n=18), the ORR is 11.1%; for FGFR2 fusions (n=6), the ORR is 0%.

The most common adverse reactions of all grades included: stomatitis (56%), fatigue (54%), diarrhea (47%), dry mouth (45%), onychomycosis (41%), poor appetite (38%), taste sensory disturbance (37%), dry skin (34%), constipation (28%), dry eye syndrome (28%), hand-foot syndrome (26%), hair loss (26%), abdominal pain (23%), and nausea (21%).

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: